Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
about
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyMen (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohortVitamin D metabolism and action in the prostate: implications for health and disease.Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values.DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study.Optimal baseline prostate-specific antigen level to distinguish risk of prostate cancer in healthy men between 40 and 69 years of ageAssociation between smoking status, and free, total and percent free prostate specific antigen.How should prostate specific antigen be interpreted?Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study.Tumor markers in prostate cancer I: blood-based markers.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.Socioeconomic determinants of prostate-specific antigen testing and estimation of the prevalence of undiagnosed prostate cancer in an elderly Polish population based on the PolSenior studyBiomarkers in prostate cancer surveillance and screening: past, present, and future.Screening for prostate cancer: an update.Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerProstate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?Prostatic specific antigen for prostate cancer detection.Biomarkers for prostate cancer detection.Prostate-specific antigen screening: proRisk-based prostate cancer screening.Risk-based prostate cancer screening: who and how?The Effects of Beginning Population Based PSA Screening at Age 40.A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 yearsEvidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.Prostate cancer screening: Canadian guidelines 2011The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries.Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker.Prostate Cancer Screening.Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau).
P2860
Q33320071-BF903C69-1140-4CAD-A83F-D0DA429BBEC0Q33643656-488CFA3E-758F-4A2B-A1B0-CC64AB17BEF0Q34027269-64AEAD9B-ADC8-4E92-A05C-8F9AF4F66E00Q35022732-48854215-445D-45C9-A6CB-71611BBE625BQ35135067-BC44A82A-22A9-4EC5-81C8-5128FE7D4CA4Q35639028-8DA410AE-A021-447D-8A9B-A7D3B704D344Q35775932-3AF2FAF6-D5DB-4F17-A064-86E77E7047A9Q35993964-A7BE8F77-4386-4C46-81D6-A7438C9DC681Q36051375-EA9A4FCF-2BF9-4D3E-85C8-4A21FE592B4AQ36142693-5179A856-BED5-477E-A442-94E7AC0C6D90Q36246097-B0A53BD5-766F-4826-817C-8ABADEB832F9Q36607766-6FBFD545-9A12-4261-84B2-58CCD58A20AEQ37043425-DE1E3A48-0B77-422C-9C40-A0BEB757D9F6Q37243010-A77E0052-717C-4312-815E-E14840387984Q37300931-24941B43-6455-4E99-8531-EB3B8523C9F4Q37338478-405EB8EE-4A9B-41C0-B30D-B74ADDD679E6Q37422990-D58D05AA-F402-4F9B-AD28-5FD0950D1273Q37573519-690C0D03-542F-49D5-A7CE-4872372C10EBQ37622491-7B834242-8A19-4344-B44B-4047A7186419Q37656233-7E85364A-7AA3-4002-B5ED-DEED7D81B8C2Q37707943-9A1404BA-8BA5-4371-B21A-4555CA29B851Q37963657-2EF400AB-8472-4304-8DE8-DD7BBB1A3737Q38093463-E0C295F0-092B-49F6-A289-A6518B0FDDFDQ38607830-C0AB9CE7-4DB8-4707-B8E5-7988FC3CF5BCQ38725930-DAEEF957-6C08-4461-A5A3-AFB8A4FBAD35Q38948710-5A6F2BCC-925B-4770-A8A9-0DC8057BD828Q41975608-C24A0CFA-7720-430B-9948-190463765F8BQ42395953-788450F3-96DC-48AF-9D1C-112F4E16245DQ42848548-6066F861-E9FF-44A3-A2CF-5D0B2605F77FQ47614718-BE6FE59F-45AC-495D-8CE6-2835382A1350Q48328454-30C3723D-5E7F-41A6-94BE-8A14A38859E1Q50804094-28E8479E-43E5-4415-8934-67E142844A3DQ51549033-70668AA1-DB1B-452E-B983-31857B74EA22Q52698894-666465BC-857C-4DC2-A65F-3B54CEA9340DQ53644144-52430BCF-B209-45F2-825F-BD8D40C16417
P2860
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Baseline prostate-specific ant ...... men younger than 60 years old.
@en
Baseline prostate-specific ant ...... men younger than 60 years old.
@nl
type
label
Baseline prostate-specific ant ...... men younger than 60 years old.
@en
Baseline prostate-specific ant ...... men younger than 60 years old.
@nl
prefLabel
Baseline prostate-specific ant ...... men younger than 60 years old.
@en
Baseline prostate-specific ant ...... men younger than 60 years old.
@nl
P2093
P1433
P1476
Baseline prostate-specific ant ...... men younger than 60 years old.
@en
P2093
Brian K Suarez
Jo Ann V Antenor
Kimberly A Roehl
Robert B Nadler
William J Catalona
P304
P356
10.1016/J.UROLOGY.2005.08.040
P407
P50
P577
2006-01-25T00:00:00Z